|
| Press Releases |
|
 |
|
| Thursday, October 17, 2024 |
|
|
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules |
| Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share. more info >> |
|
| Tuesday, October 15, 2024 |
|
|
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of 1,633,987 shares of common stock at a purchase price of $3.06 per share in a registered direct offering priced at-the-market under Nasdaq rules. more info >> |
|
| Wednesday, October 9, 2024 |
|
|
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has begun, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) Zepbound (tirzepatide) in an oral dose format. more info >> |
|
| Tuesday, October 8, 2024 |
|
|
Lexaria Updates Current GLP-1 Market |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery technology, provides an update on recent glucagon-like peptide-1 ("GLP-1") receptor agonist market sector advancements. more info >> |
|
| Tuesday, October 1, 2024 |
|
|
Lexaria Appoints Michael Shankman as Chief Financial Officer |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the appointment of Michael Shankman, CPA, as Chief Financial Officer (CFO) effective immediately. As a member of the executive leadership team, Mr. Shankman will lead the Company's financial operations. more info >> |
|
| Friday, September 27, 2024 |
|
|
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that approval has been received from an independent review board, for human pilot study #3 (the "Study"), investigating a DehydraTECH-processed version of the dual action GLP-1 (glucagon-like peptide) + GIP (glucose-dependent insulinotropic peptide) tirzepatide in an oral dose format. more info >> |
|
| Thursday, September 5, 2024 |
|
|
Lexaria Releases Strategic Letter from the Outgoing CEO |
| Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this letter from outgoing Chief Executive Officer ("CEO") Chris Bunka as a strategic update to all stakeholders. more info >> |
|
|
Lexaria Welcomes Industry Veteran as New CEO |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that Chris Bunka, Chief Executive Officer ("CEO") of the Company, is stepping aside for the appointment of Richard Christopher as the new CEO, effective August 31, 2024. more info >> |
|
| Tuesday, September 3, 2024 |
|
|
Lexaria Enters a Material Transfer Agreement for DehydraTECH Research |
| Lexaria Bioscience Corp. (Nasdaq: LEXX & LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that it has entered into a Material Transfer Agreement with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECHTM technology in a pre-clinical setting. more info >> |
|
| Thursday, August 29, 2024 |
|
|
Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus Oral Capsules |
| more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Lincotrade Unveils Freehold Residential Project, The Shang Residence, in Kuala Lumpur, Malaysia
Mar 3, 2026 16:22: JST
|
|
|
Exito Media Concepts Announces the 32nd Edition of the Manufacturing IT Summit - Thailand 2026
Mar 3, 2026 16:18: JST
|
|
|
Concord New Energy Signs MOU with Bain Capital-Backed Bridge Data Centre
Mar 3, 2026 15:27 HKT/SGT
|
|
|
華領醫藥宣佈多格列艾汀在中國香港獲批上市
Mar 3, 2026 12:51 HKT/SGT
|
|
|
华领医药宣布多格列艾汀在中国香港获批上市
Mar 3, 2026 12:37 HKT/SGT
|
|
|
Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China
Mar 3, 2026 12:14 HKT/SGT
|
|
|
The Tomorrow Company Launches With a Bold Mandate to Build the Infrastructure Layer of the AI-Native Financial Era.
Mar 3, 2026 11:34: JST
|
|
|
愛康醫療(1789.HK)獲納入中證港股通機器人主題指數 凸顯機器人領域投資潛力
Mar 3, 2026 10:45 HKT/SGT
|
|
|
爱康医疗(1789.HK)获纳入中证港股通机器人主题指数 凸显机器人领域投资潜力
Mar 3, 2026 10:36 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES, 소결 금(Au) 접합기술 ‘AuRoFUSE(TM) Preforms’ 전사 기술 확립
Mar 3, 2026 10:00 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL TECHNOLOGIES 建立了燒結金(Au)接合技術「AuRoFUSE(TM) Preforms」的轉印技術
Mar 3, 2026 10:00 HKT/SGT
|
|
|
協合新能源與貝恩資本旗下Bridge Data Centres簽署諒解備忘錄
Mar 3, 2026 09:03 HKT/SGT
|
|
|
协合新能源与贝恩资本旗下Bridge Data Centres签署谅解备忘录
Mar 3, 2026 09:03 HKT/SGT
|
|
|
太平洋大道資本合夥公司旗下子公司將向IAC收購Care.com
Mar 3, 2026 08:00 HKT/SGT
|
|
|
太平洋大道资本合伙公司旗下子公司将从IAC收购Care.com
Mar 3, 2026 08:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
